Skip to content

PMD updates on the reverse share split following the reverse acquisition

PMD Device Solutions AB ("PMD" or the "Company") formerly Promore Pharma AB, carried out the reverse acquisition with the PMD group by decision of the extraordinary general meeting on 29 December 2023 and simultaneously decided on a reverse share split (1:128).

The extraordinary general meeting authorised the board of directors to determine the record date for the reverse split which is expected to be resolved upon during the month of January. The Board will, in connection with the determination of the record date for the reverse split, publish further information on the procedure for the reverse split.

For additional information, please contact:

Myles Murray, CEO

Phone: +353 86 887 4994

E-mail:; for general enquiries

The Company’s Certified Adviser is Redeye.